The Cancer Drug Development Forum (CDDF) is an international organisation registered in Austria, providing a platform for all stakeholders involved in the development of oncology drugs. The aim of the not-for-profit organization is to accelerate the delivery of effective oncology agents to patients.
Established in 2001 as the Biotherapy Development Association (BDA), the focus was initially around immunotherapy. Recognizing the importance of embracing all forms of oncology drug development, the name of the organization was changed in 2014 to the Cancer Drug Development Forum (CDDF).
CDDF mission is to lead a neutral platform to stimulate interactions between all stakeholders (academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors) in cancer drug development in order to accelerate the delivery of effective agents to patients.
The Cancer Drug Developent Forum (CDDF) was founded in 2001 in collaboration with a group of pre-clinical and clinical researchers. The organisation was named Biotherapy Development Association (BDA) until 2014, when it was renamed as Cancer Drug Development Forum (CDDF).
While BDA focus was initially around immunotherapy, in recent years the association has embraced all forms of cancer drug development and therefore wanted a name that better reflects the organisation breadth of interests.
The new name CDDF translates better the association goals and mission, of being recognized as a unique forum where all those dedicated to the development of cancer drugs can together exchange expertise to find the ways to expedite effective oncology drug development and delivery.
For the past years, CDDF has strived to leverage the discussion of the most promising advances in oncology drug development, uniting experts from academia, pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.